• P D N N Sirisena, Shakuntala Mahilkar, Chetan Sharma, Jaspreet Jain, and Sujatha Sunil.
• ImmunifyMe Healthcare Technologies Pvt. Ltd., Altrade Business Centre, Gurugram, Haryana, India.
• Indian J Med Res. 2021 May 1; 154 (5): 669679669-679.

AbstractMultiple dengue virus (DENV) serotypes circulating in a geographical area most often lead to simultaneous infection of two or more serotypes in a single individual. The occurrence of such concurrent infections ranges from 2.5 to 30 per cent, reaching as high as 40-50 per cent in certain dengue hyper-endemic areas. Concurrent dengue manifests itself differently than mono-infected patients, and it becomes even more important to understand the effects of co-infecting serotypes in concurrent infections to ascertain the clinical outcomes of the disease progression and transmission. In addition, there have also been reports of concurrent DENV infections in the presence of other arboviral infections. In this review, we provide a comprehensive breakdown of concurrent dengue infections globally. Furthermore, this review also touches upon the clinical presentations during those concurrent infections categorized as mild or severe forms of disease presentation. Another aspect of this review was aimed at providing insight into the concurrent dengue incidences in the presence of other arboviruses.

12 keywords...

hide…